CDEX Presents Pocket ID2 at 2011 NHTSA Bi-Regional Law Enforcement Training Summit

June 30, 2011, by , Posted in Press Releases, Comments Off on CDEX Presents Pocket ID2 at 2011 NHTSA Bi-Regional Law Enforcement Training Summit

TUCSON, AZ–(Marketwire – Jun 30, 2011) – CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products, using patented technologies for use in healthcare, safety and security markets, recently presented the Pocket ID2™ device at the 2011 NHTSA Bi-Regional Law Enforcement Training Summit. The training summit, which took place June 21-23, 2011 in Louisville, KY, brought together law enforcement divisions from the Southeast, Mid-Atlantic and Mid-West regions of the US.

The National Highway Traffic Safety Administration (NHTSA) training summit, held every year, provides personnel from leading law enforcement agencies the opportunity to gain exposure to the latest information and technology for increasing the effectiveness and safety for implementing successful enforcement campaigns. Attendees discover new ideas and new technology that will aid and assist them in operating safely and effectively. The summit attracts law enforcement officials, state and local highway safety professionals and advocates as well as national experts from Delaware, Illinois, Indiana, Kentucky, Maryland, Michigan, Minnesota, North Carolina, Ohio, Virginia, West Virginia, Wisconsin, and the District of Columbia.

The Pocket ID2 allows law enforcement officers and other agencies to conveniently carry a handheld device that provides immediate access for testing of methamphetamines. The Pocket ID2 was developed with CDEX’s patented technologies that detect and verify the presence of meth at the visible and prosecutable range. Test results are instantaneous and non-destructive and can be conducted without touching or disturbing the surfaces scanned, thus minimizing officer exposure and preserving the integrity of the sample substance for use as evidence. The innovative technology is designed for use in law enforcement, correctional facilities and other applications where definitive and immediate results are necessary. The company is currently developing the Pocket ID2 for testing of Cocaine and other illicit substances, which will further enhance and advance its capabilities in the future.

“We were honored to be selected to demonstrate our new Pocket ID2 detection device at the NHTSA training conference. The conference is one of the largest gatherings of law enforcement agencies in the country and provided a unique opportunity to showcase our Pocket ID2’s capabilities,” stated Jeff Brumfield, chairman and chief executive officer of CDEX. “Many of the attendees at the conference have already submitted queries for additional information and onsite demonstrations of the Pocket ID2. We continue to build interest in our ID2 drug detection device product line while continuing to assemble the necessary infrastructure and support to execute our business plan and drive future sales.”

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.

Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.